Compare CRNC & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNC | OABI |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.2M | 300.9M |
| IPO Year | N/A | N/A |
| Metric | CRNC | OABI |
|---|---|---|
| Price | $11.33 | $1.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $11.50 | $6.67 |
| AVG Volume (30 Days) | ★ 1.0M | 623.5K |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | $21,094,000.00 |
| Revenue This Year | $27.55 | N/A |
| Revenue Next Year | N/A | $66.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 3.36 |
| 52 Week Low | $5.94 | $1.22 |
| 52 Week High | $27.50 | $4.02 |
| Indicator | CRNC | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 52.52 | 54.27 |
| Support Level | $10.87 | $2.00 |
| Resistance Level | $11.65 | $2.15 |
| Average True Range (ATR) | 0.57 | 0.12 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 29.23 | 35.14 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.